Beyond Biotechnology


Book Description

In 2001 the Human Genome Project announced that it had successfully mapped the entire genetic content of human DNA. Scientists, politicians, theologians, and pundits speculated about what would follow, conjuring everything from nightmare scenarios of state-controlled eugenics to the hope of engineering disease-resistant newborns. As with debates surrounding stem-cell research, the seemingly endless possibilities of genetic engineering will continue to influence public opinion and policy into the foreseeable future. Beyond Biotechnology: The Barren Promise of Genetic Engineering distinguishes between the hype and reality of this technology and explains the nuanced and delicate relationship between science and nature. Authors Craig Holdrege and Steve Talbott evaluate the current state of genetic science and examine its potential applications, particularly in agriculture and medicine, as well as the possible dangers. The authors show how the popular view of genetics does not include an understanding of the ways in which genes actually work together in organisms. Simplistic and reductionist views of genes lead to unrealistic expectations and, ultimately, disappointment in the results that genetic engineering actually delivers. The authors explore new developments in genetics, from the discovery of "non-Darwinian" adaptative mutations in bacteria to evidence that suggests that organisms are far more than mere collections of genetically driven mechanisms. While examining these issues, the authors also answer vital questions that get to the essence of genetic interaction with human biology: Does DNA "manage" an organism any more than the organism manages its DNA? Should genetically engineered products be labeled as such? Do the methods of the genetic engineer resemble the centuries-old practices of animal husbandry? Written for lay readers, Beyond Biotechnology is an accessible introduction to the complicated issues of genetic engineering and its potential applications. In the unexplored space between nature and laboratory, a new science is waiting to emerge. Technology-based social and environmental solutions will remain tenuous and at risk of reversal as long as our culture is alienated from the plants and animals on which all life depends.




Beyond Therapy


Book Description

explores the profound ethical and social consequences of today's biotechnical revolution. Almost every week brings news of novel methods for screening genes and testing embryos, choosing the sex and modifying the behavior of children, enhancing athletic performance, slowing aging, blunting painful memories, brightening mood, and altering basic temperaments. But we must not neglect the fundamental question: Should we be turning to biotechnology to fulfill our deepest human desires? We want better children -- but not by turning procreation into manufacture or by altering their brains to gain them an edge over their peers. We want to perform better in the activities of life -- but not by becoming mere creatures of chemistry. We want longer lives -- but not at the cost of becoming so obsessed with our own longevity that we care little about future generations. We want to be happy --




Signs of Life


Book Description

The theory and practice of bio art, a new art form that uses the materials and processes of biotechnology, with examples of work by such prominent artists as Eduardo Kac and Marc Quinn. Bio art is a new art form that has emerged from the cultural impact and increasing accessibility of contemporary biotechnology. Signs of Life is the first book to focus exclusively on art that uses biotechnology as its medium, defining and discussing the theoretical and historical implications of bio art and offering examples of work by prominent artists. Bio art manipulates the processes of life; in its most radical form, it invents or transforms living organisms. It is not representational; bio art is in vivo. (A celebrated example is Eduardo Kac's own GFP Bunny, centered on "Alba," the transgenic fluorescent green rabbit.) The creations of bio art become a part of evolution and, provided they are capable of reproduction, can last as long as life exists on earth. Thus, bio art raises unprecedented questions about the future of life, evolution, society, and art. The contributors to Signs of Life articulate the critical theory of bio art and document its fundamental works. The writers—who include such prominent scholars as Barbara Stafford, Eugene Thacker, and Dorothy Nelkin—consider the culture and aesthetics of biotechnology, the ethical and philosophical aspects of bio art, and biology in art history. The section devoted to artworks and artists includes George Gessert's Why I Breed Plants, Oron Catts and Ionat Zurr's Semi-Living Art, Marc Quinn's Genomic Portrait, and Heather Ackroyd and Dan Harvey's Chlorophyll.




Life as Surplus


Book Description

Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences. The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy. At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.




Plant Biotechnology 2002 and Beyond


Book Description

The 10th IAPTC&B Congress, Plant Biotechnology 2002 and Beyond, was held June 23-28, 2002, at Disney's Coronado Springs Resort, in Orlando, Florida, USA. It was attended by 1,176 scientists from 54 countries. The best and brightest stars of international plant biotechnology headlined the scientific program. It included the opening address by the President of the IAPTC&B, 14 plenary lectures, and 111 keynote lectures and contributed papers presented in 17 symposia covering all aspects of plant biotechnology. More than 500 posters supplemented the formal program. The distinguished speakers described, discussed and debated not only the best of science that has been done or is being done, but also how the power of plant biotechnology can be harnessed to meet future challenges and needs. The program was focused on what is new and what is exciting, what is state of the art, and what is on the cutting edge of science and technology. In keeping with the international mandate of the IAPTC&B, 73 of the 125 speakers were from outside the United States, representing 27 countries from every region of the world. The 10th IAPTC&B Congress was a truly world-class event. The IAPTC&B, founded in 1963 at the first international conference of plant tissue culture organized by Philip White in the United States, currently has over 1,500 members in 85 countries. It is the largest, oldest, and the most comprehensive international professional organization in the field of plant biotechnology. The IAPTC&B has served the plant biotechnology community well through its many active national chapters throughout the World, by maintaining and disseminating a membership list and a website, by the publication of an official journal (formerly the Newsletter), and by organizing quadrennial international congresses in France (1970), the United Kingdom (1974), Canada (1978), Japan (1982), the United States (1963, 1986, 2002), The Netherlands (1990), Italy (1994), and Israel (1998). In addition, the IAPTC&B has a long tradition of publishing the proceedings of its congresses. Individually, these volumes have provided authoritative quadrennial reports of the status of international plant biotechnology. Collectively, they document the history of plant biotechnology during the 20th century. They are indeed a valuable resource. We are pleased to continue this tradition by publishing this proceedings volume of the 10th IAPTC&B Congress. Regrettably, we are not able to publish seven of the lectures in full (only their abstracts are included). The American and Canadian chapters of the IAPTC&B, the Plant Section of the Society for In Vitro Biology, and the University of Florida hosted the 10th IAPTC&B Congress. The Congress was a true partnership between academia and industry, and was generously supported by both groups (see list of donors/sponsors on back cover). A number of prominent international biotechnology companies and publishers participated in the very successful Science and Technology Exhibit (see accompanying list of exhibitors) The IAPTC&B awarded 84 fellowships to young scientists from 31 countries (see accompanying list of fellowship recipients) to support their participation in the Congress.




From Breakthrough to Blockbuster


Book Description

"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--




Preparing for Future Products of Biotechnology


Book Description

Between 1973 and 2016, the ways to manipulate DNA to endow new characteristics in an organism (that is, biotechnology) have advanced, enabling the development of products that were not previously possible. What will the likely future products of biotechnology be over the next 5â€"10 years? What scientific capabilities, tools, and/or expertise may be needed by the regulatory agencies to ensure they make efficient and sound evaluations of the likely future products of biotechnology? Preparing for Future Products of Biotechnology analyzes the future landscape of biotechnology products and seeks to inform forthcoming policy making. This report identifies potential new risks and frameworks for risk assessment and areas in which the risks or lack of risks relating to the products of biotechnology are well understood.




Beyond Bioethics


Book Description

"For several decades, the field of bioethics has played a dominant role in shaping the way society thinks about ethical problems related to developments in science, technology, and medicine. But its traditional emphases on, for example, doctor-patient relationships, informed consent, and individual autonomy have led the field to not be fully responsive to the challenges posed by new human biotechnologies such as assisted reproduction, human genetic enhancement, and DNA forensics. Beyond Bioethics provides a focused overview for students and others grappling with the profound social dilemmas posed by these developments. It brings together the work of cutting-edge thinkers from diverse fields of study and public engagement, all of them committed to a new perspective that is grounded in social justice and public interest values. The contributors to this volume seek to define an emerging field of scholarly, policy, and public concern: a new biopolitics."--Provided by publisher.




Asian Biotech


Book Description

Providing the first overview of Asia’s emerging biosciences landscape, this timely and important collection brings together ethnographic case studies on biotech endeavors such as genetically modified foods in China, clinical trials in India, blood collection in Singapore and China, and stem-cell research in Singapore, South Korea, and Taiwan. While biotech policies and projects vary by country, the contributors identify a significant trend toward state entrepreneurialism in biotechnology, and they highlight the ways that political thinking and ethical reasoning are converging around the biosciences. As ascendant nations in a region of postcolonial emergence, with an “uncanny surplus” in population and pandemics, Asian countries treat their populations as sources of opportunity and risk. Biotech enterprises are allied to efforts to overcome past humiliations and restore national identity and political ambition, and they are legitimized as solutions to national anxieties about food supplies, diseases, epidemics, and unknown biological crises in the future. Biotechnological responses to perceived risks stir deep feelings about shared fate, and they crystallize new ethical configurations, often re-inscribing traditional beliefs about ethnicity, nation, and race. As many of the essays in this collection illustrate, state involvement in biotech initiatives is driving the emergence of “biosovereignty,” an increasing pressure for state control over biological resources, commercial health products, corporate behavior, and genetic based-identities. Asian Biotech offers much-needed analysis of the interplay among biotechnologies, economic growth, biosecurity, and ethical practices in Asia. Contributors Vincanne Adams Nancy N. Chen Stefan Ecks Kathleen Erwin Phuoc V. Le Jennifer Liu Aihwa Ong Margaret Sleeboom-Faulkner Kaushik Sunder Rajan Wen-Ching Sung Charis Thompson Ara Wilson




Science Business


Book Description

Why has the biotechnology industry failed to perform up to expectations? This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. It also provides prescriptions for companies, seeking ways to improve the industry's performance.